Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis

Teclegiorgis Gebremariam; Sondus Alkhazraji; Clara Baldin; Laura Kovanda; Nathan P. Wiederhold; Ashraf S. Ibrahim

doi:10.1128/AAC.02589-16

Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis

Teclegiorgis Gebremariam
, Sondus Alkhazraji
, Clara Baldin
, Laura Kovanda
, Nathan P. Wiederhold
, Ashraf S. Ibrahim

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.

Original language	English (US)
Article number	e02589
Journal	Antimicrobial agents and chemotherapy
Volume	61
Issue number	5
DOIs	https://doi.org/10.1128/AAC.02589-16
State	Published - May 2017

Keywords

Isavuconazole
Mucormycosis
Murine
Posaconazole
Prophylaxis
Rhizopus delemar
Voriconazole

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology

Access to Document

10.1128/AAC.02589-16

Cite this

@article{d32d0a4df1814f289b3926ded5fd7ffe,

title = "Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis",

abstract = "We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.",

keywords = "Isavuconazole, Mucormycosis, Murine, Posaconazole, Prophylaxis, Rhizopus delemar, Voriconazole",

author = "Teclegiorgis Gebremariam and Sondus Alkhazraji and Clara Baldin and Laura Kovanda and Wiederhold, \{Nathan P.\} and Ibrahim, \{Ashraf S.\}",

year = "2017",

month = may,

doi = "10.1128/AAC.02589-16",

language = "English (US)",

volume = "61",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis

AU - Gebremariam, Teclegiorgis

AU - Alkhazraji, Sondus

AU - Baldin, Clara

AU - Kovanda, Laura

AU - Wiederhold, Nathan P.

AU - Ibrahim, Ashraf S.

PY - 2017/5

Y1 - 2017/5

N2 - We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.

AB - We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.

KW - Isavuconazole

KW - Mucormycosis

KW - Murine

KW - Posaconazole

KW - Prophylaxis

KW - Rhizopus delemar

KW - Voriconazole

UR - https://www.scopus.com/pages/publications/85018177860

UR - https://www.scopus.com/pages/publications/85018177860#tab=citedBy

U2 - 10.1128/AAC.02589-16

DO - 10.1128/AAC.02589-16

M3 - Article

C2 - 28264840

AN - SCOPUS:85018177860

SN - 0066-4804

VL - 61

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 5

M1 - e02589

ER -

Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this